1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc.

CLPT
ClearPoint Neuro, Inc.US flagNASDAQ Capital Market
13.96
USD
-0.09
- -
418.65MMarket Cap

Total Valuation

ClearPoint Neuro, Inc. carries a market capitalization of 418.65M, placing it among publicly traded companies globally. Its enterprise value stands at 578.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap418.65M
Enterprise Value578.76M

Share Statistics

ClearPoint Neuro, Inc. currently has 30.50M shares outstanding.

Shares Outstanding30.50M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 12.40, and the price-to-book ratio stands at 50.50.

PE RatioN/A
PS Ratio12.40
PB Ratio50.50
P/TBV Ratio-56.62
P/FCF Ratio-18.03
P/OCF Ratio-17.37

Enterprise Valuation

EV / Sales13.69
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

ClearPoint Neuro, Inc. maintains a current ratio of 4.74, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 593.41, indicating elevated leverage, while an interest coverage ratio of -5.19 demonstrates limited ability to service its debt obligations.

Current Ratio4.74
Quick Ratio3.66
Debt / Equity593.41
Debt / EBITDA-2.34
Interest Coverage-5.19

Financial Efficiency

Return on Equity (ROE)-226.52
Return on Assets (ROA)-46.21
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.09

Taxes

Income Tax-18,000.00
Effective Tax RateN/A

Stock Price Statistics

ClearPoint Neuro, Inc.'s stock has gained approximately 27.72187% over the past 52 weeks. The 50-day moving average sits at 15.61, while the 200-day moving average is 13.42.

Beta (5Y)N/A
52-Week Price Change27.72187%
50-Day Moving Average15.61
200-Day Moving Average13.42
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, ClearPoint Neuro, Inc. generated 42.28M in revenue and converted that into -34.57M in net income, yielding earnings per share of -1.18. EBITDA reached -27.28M, while operating income came in at -31.04M.

Revenue42.28M
Gross Profit26.47M
Operating Income-31.04M
Pretax Income-34.58M
Net Income-34.57M
EBITDA-27.28M
EBIT-31.04M
Earnings Per Share (EPS)-1.18

Balance Sheet

ClearPoint Neuro, Inc. holds 29.36M in cash and equivalents against 63.95M in total debt, resulting in a net debt position of 20.87M. Total book value stands at 10.78M, with working capital of 38.62M providing operational flexibility.

Cash & Cash Equivalents29.36M
Total Debt63.95M
Net Debt20.87M
Equity (Book Value)10.78M
Book Value Per Share0.35
Working Capital38.62M

Cash Flow

ClearPoint Neuro, Inc. produced -30.18M in operating cash flow over the past twelve months. After subtracting -1.11M in capital expenditures, free cash flow totaled -31.29M - equivalent to -1.06 per share.

Operating Cash Flow-30.18M
Capital Expenditures-1.11M
Free Cash Flow-31.29M
FCF Per Share-1.06

Margins

ClearPoint Neuro, Inc. operates with a gross margin of 62.61, reflecting its pricing power and cost economics. The operating margin of -73.42 and net profit margin of -81.76 provide insight into operational efficiency.

Gross Margin62.61
Operating Margin-73.42
Pretax Margin-81.80
Profit Margin-81.76
EBITDA Margin-64.52

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-3.44
FCF Yield-5.55

Stock Splits

ClearPoint Neuro, Inc.'s most recent stock split took place on July 27, 2016 with a 40:1 split ratio.

Last Split Date7/27/2016
Split Ratio40:1

Scores

ClearPoint Neuro, Inc. posts an Altman Z-Score of -0.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.93